Special Seminar: Lab-in-a-patient microdevices for next-generation precision medicine

Oliver Jonas, Postdoctoral Associate, David H. Koch Institute for Integrative Cancer Research at MIT

Monday, February 8, 2016, 3:30–4:30pm

Spanos Auditorium, Cummings Hall

The ability to predict the optimal therapy for an individual patient is a major unmet need in the treatment of cancer and other diseases. We have developed implantable microdevices that are capable of testing the phenotypic response of a large number of different anti-cancer agents within the native tumor tissue in a rapid, parallel, minimally invasive assay without inducing systemic toxicities. Up to 100 distinct therapies can be tested in a single tumor, providing insight into efficacy, signaling pathway inhibition and pharmacodynamics for each treatment option. Using multiple optical modalities integrated into the microdevices using miniaturized fiber optics, we are able to monitor the activity of each drug in real time. This approach provides new insight into drug action within tumors, and the information may be used to tailor a patient’s therapy for optimal response with minimal side effects.

About the Speaker

Oliver Jonas is a postdoctoral associate in the Langer Lab at the David H. Koch Institute for Integrative Cancer Research at MIT. Oliver's research focuses on new technologies for precision medicine, particularly through the development of microscale implantable drug delivery and sensing devices. Prior to his work at MIT, Dr. Jonas was an associate at Third Rock Ventures in Boston, and also worked as a management consultant in Germany and the US. Oliver holds a PhD in biophysics.

For more information, contact Louise Cullen at louise.a.cullen@dartmouth.edu.